Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 18/2014

01-12-2014 | Adis Drug Evaluation

Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes

Author: Greg L. Plosker

Published in: Drugs | Issue 18/2014

Login to get access

Abstract

Dapagliflozin (Forxiga®, Farxiga®) is an orally administered sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes. Dapagliflozin reduces renal glucose reabsorption by inhibiting the transporter protein SGLT2 in the renal proximal tubule, thereby increasing urinary glucose excretion and reducing blood glucose levels. Its mechanism of action is independent of insulin secretion or action; therefore, dapagliflozin provides complementary therapy when used in combination with other antihyperglycaemic drugs. This article updates an earlier review of dapagliflozin and focuses on longer-term efficacy and tolerability data (e.g. from extensions of earlier clinical trials), as well as data from studies in special patient populations (e.g. history of cardiovascular disease). Numerous well-designed clinical trials with dapagliflozin, primarily as add-on therapy for 24 weeks (but also as monotherapy or initial combination therapy), have consistently demonstrated reductions in glycosylated haemoglobin, fasting plasma glucose levels and bodyweight. Extensions of these trials show the effects are maintained over longer-term follow-up periods of ≈1–4 years and dapagliflozin is generally well tolerated. Dapagliflozin has a low risk of hypoglycaemia, although the incidence varies depending on background therapy, and genital mycotic infections (particularly in women) are the most common adverse events. Dapagliflozin is not recommended in patients with moderate or severe renal impairment. In view of its unique mechanism of action and now well-established efficacy and tolerability profile, dapagliflozin is a useful treatment option in the management of type 2 diabetes, although its effects on diabetic complications remain to be evaluated.
Literature
1.
2.
3.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.PubMedCentralPubMedCrossRef
4.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37(Suppl 1): S81–90.
5.
American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014; 37(Suppl 1): S14–80.
6.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCentralPubMedCrossRef
7.
Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.PubMedCrossRef
8.
Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.PubMedCrossRef
9.
10.
11.
Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17–27.PubMedCrossRef
12.
Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85.PubMedCrossRef
13.
Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272–7.PubMedCrossRef
14.
15.
Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137–44.PubMedCrossRef
16.
Weir GC, Marselli L, Marchetti P, et al. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab. 2009; 11(Suppl 4): 82–90.
17.
Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity. 2012;20(8):1645–52.PubMedCrossRef
18.
Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509–14.PubMedCentralPubMedCrossRef
19.
Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.PubMedCentralPubMedCrossRef
20.
Bonner C, Kerr-Conte J, Gmyr V et al. Glucose transporter SGLT2 inhibition triggers glucagon secretion in alpha cells [abstract no. 609]. Diabetologia. 2014; 57(Suppl 1): S251–2.
21.
Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405–14.PubMedCrossRef
22.
Boulton DW, Kasichayanula S, Keung CF, et al. Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75(3):763–8.PubMedCentralPubMed
23.
Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011;13(8):770–3.PubMedCrossRef
24.
Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clinical Ther. 2011;33(11):1798–808.CrossRef
25.
Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(4):357–65.PubMedCrossRef
26.
Yang L, Li H, Li H et al. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013; 35(8): 1211-22.e2.
27.
Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163–77.PubMedCrossRef
28.
Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295–304.PubMedCrossRef
29.
Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther. 2013;4(1):41–9.PubMedCentralPubMedCrossRef
30.
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33.PubMedCrossRef
31.
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–22.PubMedCentralPubMedCrossRef
32.
Rosenstock J, Vico M, Wei L. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–8.PubMedCentralPubMedCrossRef
33.
Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–38.PubMedCrossRef
34.
Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin a randomized trial. Ann Intern Med. 2012;156(6):405–15.PubMedCrossRef
35.
Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–24.PubMedCentralPubMedCrossRef
36.
Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–56.PubMedCrossRef
37.
Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740–50.PubMedCrossRef
38.
Matthaei S, Bowering K, Rohwedder K, et al. Improvement in glycemic control and reduction in body weight over 52 weeks with dapagliflozin as add-on therapy to metformin plus sulfonylurea [abstract no. 267-OR]. Diabetes. 2014; 63(Suppl 1): A70-1.
39.
Hansen L, Zee P, Li Y et al. Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs. saxagliptin or dapagliflozin add-on alone in poorly controlled type 2 diabetes on metformin [abstract no. 4]. Diabetologia. 2014; 57(Suppl 1): S8.
40.
Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11(1).
41.
Del Prato S, Nauck M, Duran-Garcia S et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data [abstract no. 62-LB]. Diabetes. 2013; 62(Suppl 1A): LB17.
42.
Strojek K, Yoon K-H, Hruba V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5(1):267–83.PubMedCentralPubMedCrossRef
43.
Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124–36.PubMedCrossRef
44.
Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111–20.PubMedCrossRef
45.
Del Prato S, Nauck M, Rohwedder K et al. Durability of glycaemic response with dapagliflozin as add-on therapy in type 2 diabetes inadequately controlled with metformin: 4-year data versus glipizide [abstract]. Diabetologia. 2014; 57(1)Suppl: 345.
46.
Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31.PubMedCrossRef
47.
Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159–69.PubMedCrossRef
48.
Grandy S, Langkilde AM, Sugg JE, et al. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract. 2014;68(4):486–94.PubMedCrossRef
49.
Grandy S, Hashemi M, Langkilde AM, et al. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014;16(7):645–50.PubMedCrossRef
50.
Grandy S, Ryden A, Sugg J et al. Weight-related quality of life and treatment satisfaction among type 2 diabetes mellitus patients treated with dapagliflozin in triple-therapy regimen [abstract no. 802-P]. Diabetes. 2014; 63(Suppl 1): A204-5.
51.
Sun YN, Zhou Y, Chen X et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014; 4(4).
52.
Orme M, Fenici P, Duprat Lomon I et al. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr. 2014; 6(1): 73.
53.
Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204–21.PubMedCrossRef
54.
Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16(5):433–42.PubMedCrossRef
55.
56.
57.
Leiter LA, Cefalu WT, de Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with pre-existing cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252–62.PubMedCrossRef
58.
Gause-Nilsson I, de Bruin TW, Sugg JE et al. Two-year efficacy and safety of dapagliflozin for T2DM patients with a history of cardiovascular disease [abstract no. 1050-P]. Diabetes. 2014; 63(Suppl 1): A271.
59.
Cefalu WT, Gause-Nilsson IA, De Bruin TW et al. Long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes, cardiovascular disease, and hypertension [abstract no. 1099-P]. Diabetes. 2014; 63(Suppl 1): A286.
60.
Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71.PubMedCentralPubMedCrossRef
61.
Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–40.PubMedCrossRef
62.
Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16(11):1102–10.PubMedCrossRef
63.
Ji L, Ma J, Li H et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1): 84–100.e9.
64.
Ji L, Li H, Mansfield T et al. Dapagliflozin as monotherapy in a Chinese population of drug-naïve patients with type 2 diabetes [abstract no. PD-0708]. In: World Diabetes Congress; 2–6 Dec 2013; Melbourne.
65.
Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014. doi:10.​1007/​s13300-014-0086-7.
66.
Yang W, Han P, Liu B et al. Dapagliflozin (DAPA) reduces HbA1c in Asian patients with T2DM after metformin (MET) failure [abstract no. 1076-P]. Diabetes. 2014; 63(Suppl 1): A279.
67.
Katz A, Yeh H, Sugg J et al. Efficacy of dapagliflozin in patients with type 2 diabetes mellitus and baseline HbA1c = 9.0 % [abstract no. 1094-P]. Diabetes. 2014; 63(Suppl 1): A284–5.
68.
Fioretto P, De Bruin T, Johnsson E et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes [abstract no. 954]. Diabetologica. 2013; 56(Suppl 1): S383.
69.
Sjostrom D, Ptaszynska A, List J et al. Dapagliflozin lowers blood pressure in patients with type 2 diabetes [abstract no. 2418-PO]. Diabetes. 2014; 63(Suppl 1): A613.
70.
Weber MA, Mansfield TA, Alessi F et al. Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker [abstract no. 13144]. Circulation. 2013; 128 Suppl.(22).
71.
Weber MA, Mansfield TA, T’Joen C et al. Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen [abstract no. 13165]. Circulation. 2013; 128 Suppl.(22).
72.
Woo V, Leiter LA, Cefalu WT et al. Blood pressure reduction with dapagliflozin in patients with type 2 diabetes and cardiovascular disease [abstract no. 10606]. Circulation. 2013; 128 Suppl.(22).
73.
Lambers Heerspink HJ, de Zeeuw D, Wie L et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9): 853–62.
74.
Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373–81.PubMedCrossRef
75.
Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complic. 2013;27(5):479–84.CrossRef
76.
Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complic. 2013;27(5):473–8.CrossRef
77.
Rohwedder K, Parikh SJ, Johnsson E. Lower risk of hypoglycemic events with dapagliflozin than glipizide over 4 years in a phase 3 study [abstract no. 2218-PO]. Diabetes. 2014; 63(Suppl 1): A563-4.
78.
Ptaszynska A, Mansfield T, Johnsson E et al. Long-term renal safety with dapagliflozin treatment [abstract no. 1036-P]. Diabetes. 2014; 63(Suppl 1): A267.
79.
Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75–83.PubMedCentralPubMedCrossRef
80.
Johnsson K, Johnsson E, Mansfield T et al. Diuresis-related safety and tolerability of dapagliflozin (DAPA) in T2DM over 24 weeks [abstract no. 1031-P]. Diabetes. 2014; 63(Suppl 1): A265.
81.
de Bruin TW, Leiter LA, Cefalu WT, et al. Dapagliflozin in patients with type 2 diabetes and established cardiovascular disease: hypotension and volume-related safety [abstract no. 10677]. Circulation. 2013;128(Suppl):1.
82.
Hardy E, Ptaszynska A, de Bruin T, et al. Changes in lipid profiles of patients with type 2 diabetes millitus on dapagliflozin therapy [abstract no. 947]. Diabetologia. 2013;56(Suppl. 1):S379.
83.
Sonesson C, Frederich R, Johansson PA, et al. Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk [abstract no. P6094]. Eur Heart J. 2014;35(Suppl. 1):1072.
84.
85.
Ljunggren O, Bolinder J, Johansson L et al. Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin [abstract]. Diabetologia. 2012; 55(Suppl 1): 748.
86.
Ptaszynska A, Mansfield T, Apanovich AM et al. Dapagliflozin, selective SGLT2 inhibitor, does not increase risk of fractures [abstract no. 1085-P]. Diabetes. 2014; 63(Suppl 1): A282.
87.
Yavin Y, Mansfield T, Ptaszynska A et al. Hyperkalemia incidence with the SGLT2 inhibitor dapagliflozin [abstract no. 1086-P]. Diabetes. 2014; 63(Suppl 1): A282.
88.
Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5(1):73–96.PubMedCentralPubMedCrossRef
89.
90.
Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(5):92–100.PubMedCrossRef
91.
Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807–24.PubMedCrossRef
92.
Henry RR, Rosenstock J, Chalamandaris A-G, et al. Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study [abstract no. 992]. Diabetologia. 2013;56(Suppl 1):S398.
93.
Kasichayanula S, Griffen SC, Chalamandaris A et al. Dapagliflozin, a selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 1 diabetes mellitus [abstract no. PI-008]. Clin Pharmacol Ther. 2014; 95(Suppl 1): S19-20.
94.
Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2014. doi:10.​1016/​j.​pcd.​2014.​04.​007.PubMed
95.
Van Haalen HGM, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135–46.PubMedCrossRef
96.
Bergenheim K, Grandy S, Wygant GD. Cost of achieving relevant composite endpoint of HbA1c < 7 %, no hypoglycaemia and weight loss of ≥3 % in a 52 week post-hoc analysis of dapagliflozin versus glipizide [abstract no. PDB45]. Value Health. 2013;16:A439.CrossRef
97.
Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin (Forxiga) versus a DPP-4 inhibitor in the treatment of type 2 diabetes mellitus (T2DM) in England and Wales [abstract no. PDB54]. Value Health. 2013;16:A440.CrossRef
98.
Abad Paniagua EJ, Casado Escribano P, Fernandez Rodriguez JM et al. Cost-effectiveness analysis of dapaglifozin versus other T2DM treatments in the Spanish context [abstract no. PDB47]. Value Health. 2013; 16: A439.
99.
Elgart JF, Prestes M, Gonzalez L, et al. Dapagliflozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Colombia [abstract]. Value Health. 2014;17:A247.CrossRef
100.
Elgart JF, Prestes M, Gonzalez L, et al. Dapagliflozin: cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile [abstract]. Value Health. 2014;17:A248.
101.
Gordon J, Bell K, Shah M, et al. Weight gain, hypoglycaemia and cost-effectiveness: what drives value among type 2 diabetes treatments in the short term [abstract]. Value Health. 2014;17:A251.CrossRef
102.
Gordon J, Bell K, Shah M, et al. Importance of longer-term follow-up data in estimating cost-effectiveness of new treatments for type 2 diabetes [abstract no. 1195-P]. Diabetes. 2014; 63(Suppl 1): A311.
103.
Neslusan C, Teschemaker A, Martin S, et al. Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the United States [abstract]. Value Health. 2014;17:A248.CrossRef
Metadata
Title
Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
Author
Greg L. Plosker
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 18/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0324-3

Other articles of this Issue 18/2014

Drugs 18/2014 Go to the issue

Adis Drug Evaluation

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

Adis Drug Evaluation

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

Acknowledgement to Referees

Acknowledgement to Referees

Erratum

Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

Adis Drug Evaluation

Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes

R&D Insight Report

Ripasudil: First Global Approval